Advertisement
Advertisement
CRSP
CRISPR Therapeutics AG
47.11
USDSponsored
+0.68
+1.47%
Mar 25, 16:00 UTC -4
Closed
After-Market
47.22
+0.11
+0.24%
CRSP Earnings Reports
Positive Surprise Ratio
CRSP beat 20 of 38 last estimates.
53%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.93M
/-$1.25
Implied change from Q4 25 (Revenue/ EPS)
+123.46%
/-8.76%
Implied change from Q1 25 (Revenue/ EPS)
+123.20%
/-20.89%
CRISPR Therapeutics AG earnings per share and revenue
On Feb 12, 2026, CRSP reported earnings of -1.37 USD per share (EPS) for Q4 25, missing the estimate of -1.17 USD, resulting in a -16.65% surprise. Revenue reached 864.00 thousand, compared to an expected 4.33 million, with a -80.03% difference. The market reacted with a +8.46% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 14 analysts forecast an EPS of -1.25 USD, with revenue projected to reach 1.93 million USD, implying an decrease of -8.76% EPS, and increase of 123.46% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were CRISPR Therapeutics AG's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, CRISPR Therapeutics AG reported EPS of -$1.37, missing estimates by -16.65%, and revenue of $864.00K, -80.03% below expectations.
How did the market react to CRISPR Therapeutics AG's Q4 2025 earnings?
The stock price moved up 8.46%, changed from $48.93 before the earnings release to $53.07 the day after.
When is CRISPR Therapeutics AG expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for CRISPR Therapeutics AG's next earnings report?
Based on 14
analysts, CRISPR Therapeutics AG is expected to report EPS of -$1.25 and revenue of $1.93M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement